Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock repurchase program of up to $1 million of the company's outstanding common stock. This program reflects the Board's confidence in the company's long-term strategy and commitment to enhancing shareholder value.
劍橋，馬薩諸塞州，2024年11月25日(GLOBE NEWSWIRE) - 愛文思控股公司(Nasdaq: ERNA)，一家電芯療法領導者，今日宣佈其董事會已授權公司回購高達 $100萬 的流通普通股的股票回購計劃。該計劃反映了董事會對公司長期策略的信心，並承諾增強股東價值。
Under the stock repurchase program, the repurchases may be made by the Company from time to time through open market transactions, privately negotiated transactions, or other means in accordance with applicable securities laws. The timing and amount of repurchases will be determined by the company's management, taking into consideration market conditions, stock price, and other factors. The program does not have a set expiration date and may be suspended, modified or discontinued at any time without prior notice.
根據股票回購計劃，公司可隨時通過公開市場交易、私下協商交易或其他方式按照適用證券法進行回購。回購的時間和金額將由公司管理層決定，考慮到市場情況、股價和其他因素。該計劃沒有設定到期日期，可以隨時在不事先通知的情況下暫停、修改或終止。
"This buyback program underscores our belief in Eterna Therapeutics' trajectory," says Sanjeev Luther, President and CEO. For more information, please visit .
「這一回購計劃彰顯了我們對愛文思控股發展方向的信心，」總裁兼首席執行官山傑夫·盧瑟表示。欲了解更多信息，請訪問。
About Eterna Therapeutics Inc.
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, with an initial emphasis on triple-negative breast cancer (TNBC) and platinum-resistant, TP53-mutant ovarian cancer. The company is currently focused on advancing its lead product ERNA-101, an induced allogenic mesenchymal stem cell ("iMSC") product, designed to selectively deliver the pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment (TME) in order to drive significant anti-tumor immunity. ERNA-101 is built on the company's in-licensed core technology, which utilizes a best-in-class approach to engineer allogenic iPSCs to express genes of interest and to efficiently differentiate these cells into iMSCs. For more information, please visit .
關於愛文思控股治療公司
愛文思控股是一家公開交易的處於臨床前階段的公司，專注於利用尖端工具提供高度創新、有效和安全的現貨細胞療法，用於治療先進固體腫瘤，首要關注三陰性乳腺癌（TNBC）和鉑金耐藥、TP53突變卵巢癌。公司目前致力於推進其主導產品ERNA-101，一種誘導異基因間充質幹細胞（「iMSC」）產品，旨在選擇性地向腫瘤微環境（TME）傳遞促炎性細胞因子IL-7和IL-15，以推動顯著的抗腫瘤免疫。ERNA-101基於該公司獲得許可的核心技術，利用一流的方法工程化異基因iPSCs，使其表達感興趣的基因，並使這些細胞高效分化爲iMSCs。欲了解更多信息，請訪問。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to if and when the Company will repurchase the stock authorized by its Board and the impact of the buyback program to the Company and its shareholders. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
前瞻性聲明
本新聞稿包含《1933年證券法》第27A條修正案和《1934年證券交易法》第21E條修正案的前瞻性陳述，此類陳述旨在受1995年《私人證券訴訟改革法》的安全港條款保護。前瞻性陳述有時可通過諸如"相信"，"可能"，"將"，"估計"，"持續"，"預期"，"設計"，"打算"，"期望"，"可能"，"計劃"，"潛在"，"預測"，"尋求"，"應當"，"將"，"考慮"，"項目"，"目標"或這些詞的否定形式和類似表達識別。前瞻性陳述涉及已知和未知風險，不確定性和可能導致Eterna在本新聞稿中的前瞻性陳述所反映的未來結果，績效或成就與實際結果，績效或成就明顯不同的其他因素。這些風險和不確定性包括，但不限於，有關公司何時是否回購其董事會授權的股票以及回購計劃對公司及其股東的影響。前瞻性陳述基於Eterna目前的期望，並涉及可能永遠無法實現或可能證明不正確的假設。所有前瞻性陳述均在其整體上受到這些建議性陳述的明確限制。歡迎查閱Eterna向美國證券交易委員會提交的文件，包括最近提交的8-k表，10-k表和10-Q表，以獲取關於Eterna風險和不確定性的詳細描述。請注意不要過分依賴前瞻性陳述，這些陳述僅根據其發佈日期發表。Eterna不承擔更新本新聞稿中包含的前瞻性陳述以反映此後發生的事件或存在的情況的任何義務，除非適用法律規定。
Investor Relations Contact:
投資者關係聯繫人：
investors@eternatx.com
investors@eternatx.com
譯文內容由第三人軟體翻譯。
